Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocodone SCHEMBL12638883 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL10440385 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL2987 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL17523150 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL101731 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12013631 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL6744988 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL277572 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL21335350 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| Hydrocodone SCHEMBL12369421 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273888-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273888-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-7985858-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985858-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100197921-A1 | Preparation of N-Alkylated Opiates by Reductive Amination | MALLINCKRODT ENTERPRISES LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197921-A1 | Preparation of N-Alkylated Opiates by Reductive Amination | MALLINCKRODT ENTERPRISES LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010065441-A1 | PROCESS FOR PREPARING HYDROCODONE USING A SUPER ACID | MALLINCKRODT INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100113788-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113788-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100041888-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT ENTERPRISES LLC | 2010-02-18 | — | — | US | disclosed |
| US-20100041888-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT ENTERPRISES LLC | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197921-A1 | Preparation of N-Alkylated Opiates by Reductive Amination | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20100113788-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | OPRK1, OPRM1, CYP2D6 | OPRD1 5/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20100041888-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.